BBC - ETF AI Analysis
Top Page
Virtus LifeSci Biotech Clinical Trials ETF (BBC)
BBC vs. SPDR S&P 500 ETF (SPY)
- AUM
- 40.28M
- Region
- North America
- Expense Ratio
- 0.65%
- Beta
- 1.39
- Issuer
- Virtus
- Inception Date
- Dec 16, 2014
- Dividend Yield
- 1.56%
- Asset Class
- Equity
- Index Tracked
- LifeSci Biotechnology Clinical Trials Index
BBC Summary
BBC, the Virtus LifeSci Biotech Clinical Trials ETF, follows the LifeSci Biotechnology Clinical Trials Index and focuses on U.S. healthcare and life sciences companies running drug and treatment trials. It holds many smaller, research-driven biotech firms such as Xencor and RegenXBio, giving investors a way to bet on future medical breakthroughs in one fund instead of picking individual stocks. Someone might invest in BBC for growth potential and diversification within cutting-edge biotech. However, this ETF is concentrated in early-stage biotech companies, so its price can be very volatile and may go up and down sharply with news about clinical trial results.
How much will it cost me?
This ETF has an expense ratio of 0.65%, which means you’ll pay about $6.50 per year for every $1,000 invested. That’s higher than the average ETF because it’s a specialized, actively managed fund focused on biotech companies in clinical trials.
What would affect this ETF?
This ETF is heavily focused on U.S. biotech companies running clinical trials, so it could benefit from medical breakthroughs, supportive healthcare regulations, and strong funding for drug development. On the downside, it is sensitive to setbacks in clinical trial results, tighter rules from regulators, and changes in investor sentiment toward riskier, early-stage healthcare stocks, especially if economic conditions weaken or borrowing costs rise.
BBC Top 10 Holdings
BBC is a pure play on U.S. clinical-stage biotech, so it lives and dies by trial headlines rather than steady cash flows. Names like Kodiak Sciences and AbCellera Biologics have been rising lately, giving the fund some welcome lift, while Xencor and Amylyx look more mixed as financial worries and trial delays cool investor enthusiasm. Smaller positions such as MBX Biosciences and Definium Therapeutics are lagging, quietly weighing on returns. Overall, this is a high-risk, high-reward basket concentrated in experimental health care rather than diversified, mature pharma giants.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 KOD | Kodiak Sciences | 2.00% | $799.21K | $5.84B | 375.24% | 35Underperform |
 TRAX | First Tracks Biotherapeutics Inc | 1.94% | $776.05K | $1.48B | 127.05% | ―― |
 ABCL | AbCellera Biologics | 1.72% | $688.57K | $3.79B | 107.86% | 49Neutral |
 XNCR | Xencor | 1.66% | $665.04K | $1.85B | 94.43% | 59Neutral |
 AMLX | Amylyx Pharmaceuticals Inc | 1.55% | $621.40K | $3.64B | 92.78% | 52Neutral |
 ORIC | Oric Pharmaceuticals | 1.31% | $523.01K | $1.43B | 12.83% | 43Neutral |
 SLS | SELLAS Life Sciences Group | 1.15% | $459.99K | $2.42B | 482.05% | 43Neutral |
 NRIX | Nurix Therapeutics | 1.19% | $477.60K | $2.84B | 139.98% | 54Neutral |
 MBX | MBX Biosciences, Inc. | 1.13% | $450.91K | $2.60B | 241.41% | 38Underperform |
 SGP | SpyGlass Pharma | 1.21% | $485.64K | $875.00M | 6.89% | ―― |
BBC Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For BBC, the sentiment is Negative. The current price of 42.13 is below the 20-day moving average (MA) of 43.18, below the 50-day MA of 48.40, and below the 200-day MA of 45.56, indicating a bearish trend. The MACD of -1.91 indicates Negative momentum. The RSI at 41.09 is Neutral, neither overbought nor oversold. The STOCH value of 63.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BBC.
BBC Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| BBC | $42.13 | $41.00(-2.68% Downside) | $40.28M | 0.65% | 43Neutral |
 RIET | $8.28 | $9.69(16.97% Upside) | $95.54M | 0.50% | 54Neutral |
 ACES | $25.68 | $41.90(63.15% Upside) | $93.15M | 0.55% | 62Neutral |
 MILN | $44.41 | $53.95(21.49% Upside) | $89.32M | 0.50% | 71Outperform |
 ASD | $27.51 | $34.24(24.47% Upside) | $1.36M | 0.79% | 62Neutral |
 TRUH | $31.63 | $33.58(6.17% Upside) | $584.29K | 0.10% | 73Outperform |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BBC | Virtus LifeSci Biotech Clinical Trials ETF | 42.13 | 10.77 | 34.35% | |
| RIET | Hoya Capital High Dividend Yield ETF | 8.28 | -0.23 | -2.71% | |
| ACES | ALPS Clean Energy ETF | 25.68 | -9.69 | -27.39% | |
| MILN | Global X Millennial Consumer ETF | 44.41 | -4.98 | -10.09% | |
| ASD | Defiance Autism Impact ETF | 27.51 | 2.65 | 10.66% | |
| TRUH | VanEck Healthcare TruSector ETF | 31.63 | 6.23 | 24.52% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.